Uptake of novel statistical methods for early-phase clinical studies in the UK public sector

Clinical Trials

Volumn 10, Issue 2, 2013, Pages 344-346

  Jaki, Thomas ^a  

^a LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BAYES THEOREM; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COMPUTER PROGRAM; FUNDING; HUMAN; ORGANIZATION AND MANAGEMENT; PRIORITY JOURNAL; QUESTIONNAIRE; STATISTICAL ANALYSIS; UNITED KINGDOM;

BAYES THEOREM; CLINICAL TRIALS AS TOPIC; DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; DECISION MAKING; GREAT BRITAIN; HUMANS; PUBLIC SECTOR;

EID: 84876557281     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774512474375     Document Type: Article

References (11)

1. Krams M, Burman C-F, Dragalin V, et al. Adaptive designs in clinical drug development: Opportunities, challenges, and scope reflections following PhRMA's November 2006 workshop. J Biopharm Stat. 2007 ; 17: 957-64
2. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chro Dis. 1960 ; 13: 346-53
3. Carter SK The Design of Clinical Trials in Cancer Therapy. Staquet MJ, ed. Mount Kisco, NY: Futura Publishing Co. ; 1973: 242-89.
4. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 ; 10: 1-10
5. Tighiouart M, Rogatko A, Babb J. Flexible Bayesian methods for cancer phase I clinical trials: Dose escalation with overdose control. Stat Med. 2005 ; 24: 2183-96
6. Whitehead J, Jaki T. One- and two-stage design proposals for a phase II trial comparing three active treatments with control using an ordered categorical endpoint. Stat Med. 2009 ; 28: 828-47
7. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics. 1990 ; 46: 33-48
8. Rogatko A, Schoeneck D, Jonas W, et al. Translation of innovative designs into phase I trials. J Clin Oncol. 2007 ; 25: 4982-86
9. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer trials. J Natl Cancer I. 2009 ; 101: 708-20
10. Guidance for Industry. Adaptive design clinical trials for drugs and biologics. Draft guidance, February2010. Available at: www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf
11. Guidance for Industry. Guidance for the use of Bayesian statistics in medical device clinical trials. Guidance, February2010. Available at: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/ GuidanceDocuments/ucm071121.pdf